Product Name:N-(5-Bromo-2-(trifluoromethoxy)phenyl)acetamide

IUPAC Name:N-[5-bromo-2-(trifluoromethoxy)phenyl]acetamide

CAS:392726-69-1
Molecular Formula:C9H7BrF3NO2
Purity:95%
Catalog Number:CM183707
Molecular Weight:298.06

Packing Unit Available Stock Price($) Quantity
CM183707-1g in stock ƈŤ
CM183707-5g in stock ħŌƚ
CM183707-10g in stock ƚǸƈ

For R&D use only.

Inquiry Form

   refresh    

Product Details

CAS NO:392726-69-1
Molecular Formula:C9H7BrF3NO2
Melting Point:-
Smiles Code:CC(NC1=CC(Br)=CC=C1OC(F)(F)F)=O
Density:
Catalog Number:CM183707
Molecular Weight:298.06
Boiling Point:
MDL No:MFCD02317366
Storage:Store at 2-8°C.

Category Infos

Benzenes
Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

Column Infos

Onvansertib
Polo-like kinase 1 (PLK1) is a key regulator of the cell-cycle progression found in human cancers, and a potential therapeutic target for oncology drug development. The recent journal Clinical Cancer Research details the Phase 1b Study of Onvansertib in combination with chemotherapy+bevacizumab treatment for patients with patients with KRAS-mutated metastatic colorectal cancer (mCRC).
Cardiff Oncology’s novel inhibitor, Onvansertib effectively targets PLK1, that prevents from tumor cell growth. It aids restore DNA damage and promote the efficacy of the standard of care therapy in a number of indications.